Evidence map›Paper›PMID 35967424›Full record

ArticleFrontiers in immunology2022

Immunosuppressive landscape in hepatocellular carcinoma revealed by single-cell sequencing.

Yi Bai, Dapeng Chen, Chuanliang Cheng, Zhongmin Li, Hao Chi, Yuliang Zhang, Xiaoyu Zhang, Shaohai Tang, Qiang Zhao, Bing Ang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Yi BaiDepartment of Hepatobiliary Surgery, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Dapeng ChenTianjin First Central Hospital Clinic Institute, Tianjin Medical University, Tianjin, China.
Chuanliang ChengTianjin First Central Hospital Clinic Institute, School of Medicine, Nankai University, Tianjin, China.
Zhongmin LiTianjin First Central Hospital Clinic Institute, Tianjin Medical University, Tianjin, China.
Hao ChiTianjin First Central Hospital Clinic Institute, Tianjin Medical University, Tianjin, China.
Yuliang ZhangTianjin First Central Hospital Clinic Institute, Tianjin Medical University, Tianjin, China.
Xiaoyu ZhangTianjin First Central Hospital Clinic Institute, Tianjin Medical University, Tianjin, China.
Shaohai TangTianjin First Central Hospital Clinic Institute, Tianjin Medical University, Tianjin, China.
Qiang ZhaoCollege of Life Sciences, Nankai University, Tianjin, China.
Bing AngOncology Department, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Yamin ZhangDepartment of Hepatobiliary Surgery, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Tianjin Medical University · CNNankai University · CNTianjin First Center Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aims: Hepatocellular carcinoma (HCC), accounting for 75-85% of primary liver cancer cases, is the third leading cause of cancer-related death worldwide. The purpose of this research was to examine the tumor immune microenvironment (TIME) in HCC. Methods: We investigated the HCC TIME by integrated analysis of single-cell and bulk-tissue sequencing data to reveal the landscape of major immune cell types. Results: Regulatory T(Treg) cells were found to be specifically distributed in the TIME of HCC. Several immune checkpoints, including TNFRSF4, TIGIT and CTLA4, were found to be uniquely overexpressed in Treg cells, and the glycolysis/gluconeogenesis pathway was enriched in Treg cells. We also discovered the presence of two NK-cell subsets with different cytotoxic capacities, one in an activated state with antitumor effects and another with an exhausted status. In addition, memory B cells in HCC were found to exist in a unique state, with high proliferation, low differentiation, and low activity, which was induced by overexpression of PRAP1 and activation of the MIF-CD74 axis. Conclusions: We revealed the TIME landscape in HCC, highlighting the heterogeneity of major immune cell types and their potential mechanisms in the formation of an immunosuppressive environment. Hence, blocking the formation of the TIME could be a useful therapeutic strategy for HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsHumansImmunosuppressive AgentsT-Lymphocytes, RegulatoryTumor MicroenvironmentImmunosuppressive Agentshepatocellular carcinomaprimary liver cancerprognosissingle cell sequencingtumor immune microenvironment

Identifiers

PMID35967424
PMCPMC9365996
OpenAlexW4288074375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.